Ultimovacs remains committed to continuing the clinical development strategy and exploring multiple pathways for UV1.The negative INITIUM results have had important consequences for the Company..
Readout of topline result expected in March 2024 from UV1 randomized Phase II trial INITIUM in Ultimovacs’ lead indication, advanced malignant melanomaTopline result will report primary endpoint of.
Oslo, 22 August 2023: Ultimovacs ASA , a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces its second quarter 2023 results today. “In the first half of this.
Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
30 patients treated with UV1/pembrolizumab24-month survival rate of 73%Promising survival data follows encouraging clinical response rates and good safety Oslo, 20 June 2022: Ultimovacs ASA ("Ultimovacs")